Article Text

Download PDFPDF

Combining cervical cancer screening for mothers with schoolgirl vaccination during human papillomavirus (HPV) vaccine implementation in South Africa: results from the VACCS1 and VACCS2 trials
Free
  1. Greta Dreyer1,
  2. Matthys H Botha2,
  3. Leon C Snyman1,
  4. Cathy Visser1,
  5. Riekie Burden3,
  6. Nicolene Laubscher4,
  7. Bertha Grond3,
  8. Karin Richter5,
  9. Piet J Becker6,7,
  10. Justin Harvey8 and
  11. Frederick H van der Merwe2
  1. 1 Obstetrics and Gynaecology, University of Pretoria Faculty of Health Sciences, Pretoria, South Africa
  2. 2 Obstetrics and Gynaecology, University of Stellenbosch, Stellenbosch, South Africa
  3. 3 HPV Cervical Cancer Research Fund, Pretoria, South Africa
  4. 4 HPV Cervical Cancer Research Fund, Cape Town, South Africa
  5. 5 Medical Virology, University of Pretoria Faculty of Health Sciences, Pretoria, South Africa
  6. 6 Faculty Research Office, University of Pretoria Faculty of Health Sciences, Pretoria, South Africa
  7. 7 Biostatistics Unit, South African Medical Research Council, Pretoria, South Africa
  8. 8 Centre for Statistical Consultation, University of Stellenbosch, Stellenbosch, South Africa
  1. Correspondence to Professor Greta Dreyer, Obstetrics and Gynaecology, University of Pretoria Faculty of Health Sciences, Pretoria, Gauteng, South Africa; gretadreyer{at}mweb.co.za

Abstract

Objective The platform provided by human papillomavirus (HPV) vaccination for linked public health interventions to improve cervical cancer prevention remains incompletely explored. The Vaccine And Cervical Cancer Screen (VACCS) cross-sectional observation trials aimed to evaluate the efficacy of school-based HPV vaccination linked with maternal cervical cancer screening.

Methods Girls from 29 schools in two provinces in South Africa were invited in writing to receive HPV vaccination. Two approaches to informed consent were compared, namely an audiovisual presentation (VACCS1) and in written format (VACCS2). Markers of vaccine uptake and coverage were calculated, namely uptake among the invited and consented cohorts, and rates of completion and sufficient vaccination. Mothers and female guardians received educational material about cervical cancer, and either a self-sampling device or an invitation to attend existing screening facilities. Knowledge was assessed via structured questionnaires (before and after), and screening uptake was self-reported and directly assessed and compared between these approaches.

Results Vaccine acceptance among 5137 invited girls was similar for the two methods of consent; 99.3% of consented girls received a first dose; overall completion rate was 90.5%. More girls were vaccinated using a two-dose (974/1016 (95.9%)) than a three-dose regimen (1859/2030 (91.6%)). The questionnaire (n=906) showed poor maternal knowledge which improved significantly (p<0.05) after health education; only 54% of mothers reported any previous screening. The offer of a self-sampling device (n=2247) was accepted by 43.9% of mothers, but only 26% of those invited to screen at existing facilities (n=396) reported subsequent screening.

Conclusions Successful linking of primary health interventions to control cervical cancer was demonstrated. School-based HPV vaccination, linked to health education, self-sampling, and molecular screening resulted in significant improvements in knowledge and screening.

  • cervical cancer

Data availability statement

Data are available upon reasonable request.

Statistics from Altmetric.com

HIGHLIGHTS

  • A vaccine acceptance rate of ~60% was reached in an opt-in program requiring parental signed informed consent.

  • Use of oral presentations almost doubled the number of mothers with knowledge about cervical cancer.

  • Cervical self-screening was accepted by 47% of previously unscreened mothers of vaccine recipients.

Introduction

Among women aged 15 to 44 years in South Africa, cervical cancer is the most common cancer, estimated to annually affect more than 10 000 women.1 2 The high prevalence, as well as late presentation and poor survival, of cervical cancer in South Africa have been attributed to the HIV epidemic, deficits in health infrastructure and the screening program, poverty, and lifestyle factors which all contribute to high rates of human papillomavirus (HPV) infection and persistence, pre-cancerous lesions, and cancer.1–6 South Africa urgently needs a functional, integrated, and effective cervical cancer prevention program to revert this epidemic. Both primary and secondary prevention strategies are essential to address the cancer risk of current and future generations.7

In view of its efficacy and cost-effectiveness, school-based HPV vaccination is a major health priority for South Africa. Examples of successful cytology-based screening programs in the developing world are rare or absent. In South Africa, coverage of the screening program is low and has limited success to reach groups at highest risk. Several studies have demonstrated a lack of knowledge and awareness of the disease, which may contribute to poor health-seeking behavior.8–10 In addition, failure to communicate and treat after positive screening is common. Finding alternative methods to reach the screening target population, improve their knowledge, and communicate results must be a priority and will require innovative approaches.

School-based HPV vaccination programs may serve as a novel platform to offer education and screening to adult female relatives, but the optimal way to link these preventive methods has not been determined.11–13 We therefore conducted two cross-sectional observation trials as part of the VACCS initiative (Vaccine And Cervical Cancer Screen trials) to study different approaches to the potential linkage between HPV vaccination, education, and screening.

The primary objective of this study was to evaluate whether HPV vaccine implementation can be linked successfully with other health interventions to improve maternal cervical cancer knowledge and screening. The secondary objective was to describe determinants of adolescent HPV vaccine uptake and completion. This is a combined report of the VACCS1 and VACCS2 trials which were both conducted in the Gauteng and Western Cape provinces of South Africa.14–16 Following the initial reports of these studies, HPV vaccine roll-out to primary school girls was initiated by the National Department of Health.

Methods

Study protocols and procedures were approved by the institutional human research ethics review committees of the Universities of Pretoria (VACCS1: 219/2009; VACCS2: 90/2013) and Stellenbosch (N11/01/008). Approval to conduct the trials at primary public schools was obtained from national and provincial Departments of Health and Basic Education and local school governing bodies. Written informed consent was obtained from all subjects, or the parents or legal guardians for minor subjects. The selection and recruitment of schools and the vaccination procedures for the first two studies were similar and previously reported.14 15 Study size was based on the availability of donated vaccine dosages. The intention during VACCS1 was vaccination with the standard registered three doses of either quadrivalent or bivalent vaccine.

During VACCS2 only the bivalent vaccine was used and intended as two doses with a 6-month interval. At the time, data convincingly demonstrated that two doses were sufficient for young girls.17

Vaccination

Parents could provide consent for vaccination of their daughters during the education events or without attending (first study) or were asked to complete and sign consent documents which were sent home (remote consent, second study). No girl was vaccinated without her own written and implied assent. Girls younger than 12 years needed parental consent by law. The vaccination process has been described previously.14 15

Health Education

In VACCS1, parents received a printed invitation to an after-hours health education event at the school. During these events, information about the disease, its development, clinical presentation, and prevention by vaccination and screening was shared using an audiovisual presentation. During VACCS2, extensive information about cervical cancer prevention options and about the study was offered to parents in a printed format, delivered home by the girl herself.

A questionnaire was developed, tested, and validated in a small pilot study for use in VACCS1. Using this administered questionnaire, information from parent participants was acquired on demographics, knowledge of cervical cancer symptoms and prevention, as well as healthcare behavior. The same questions were repeated after 3 months to determine changes in knowledge and participant-reported screening behavior to evaluate the efficacy of the educational intervention.

Screening

Mothers were invited to screen using three approaches: invitations to attend existing facilities (VACCS1); tampons and transport medium (with information to use) handed out directly for self-collected screening (VACCS1); and Evalyn self-samplers sent home in a sealed package (VACCS2, both provinces). Screening was indicated for any woman with a uterus without recollection of previous screening in the last 5 years.

Information from the questionnaires were used to describe the demographics of the screening cohort and to calculate the size of the unscreened cohorts. All self-collected samples were tested with HPV DNA tests, while samples collected at existing facilities were tested in the standard way using cytology. We determined changes in screening behavior using self-reporting and by calculating participation in HPV and cytological screening options.

Data Management

For analysis and comparison of the vaccination data of VACCS1 and VACCS2, girls enrolled in the targeted grades made up the invited cohort, and those with written parental and child consent made up the consented cohort. We defined the consented cohort for these studies as all those who consented to receive the vaccine. The vaccinated cohort were all girls who received at least one dosage, while all who received at least two doses, 6 months or more apart, were considered sufficiently vaccinated.14 Uptake, completion, and sufficiently vaccinated rates were calculated for the different cohorts and compared between the studies, using the relevant cohort denominator.

The two questionnaires were compared per participant to determine the impact of the project on knowledge and behavior as previously described.18 The number of women who attended existing screening facilities (VACCS1) after the health education event was determined by accessing data from the local screening registry.

The total target group for screening was all adult women available to participate; the unscreened target group was calculated from the percentage of participants indicating no screening in the last 5 years. The screened cohort included everyone who reported an improvement in screening in the previous 12 months (VACCS1) and women who handed in self-collected samples (VACCS1 and VACCS2). The invited cohort were all women verified to have received an invitation to participate in screening. Uptake rates and positive screening rates were calculated using these different cohorts, as well as the test results.

Statistical analysis was performed using Statistica statistical software. A p value <0.05 was considered statistically significant. In accordance with this journal’s guidelines, all data required for the reproducibility of this study in other centers will be provided on request.

Results

We invited 3465 primary school girls attending 19 schools during VACCS1 (2011–2013) and 1672 girls in 10 schools in the same districts during VACCS2 (2013–2014). From these, 2619 mother–daughter pairs were invited from Gauteng Province and 2518 pairs from the Western Cape. Vaccination data are shown in Table 1.

Table 1

Vaccine coverage

Vaccination

Written parental consent and child assent for vaccination were obtained from 3068 of 5137 (59.7%) girls. Invited uptake rates were 59.0% for VACCS1 versus 61.1% for VACCS2, with no difference between the two strategies to inform and invite girls to this opt-in program. Almost 90% of parents who attended a health education event consented, but this was offset by relatively low attendance rates (Table 1).

Only 22 (0.7%) children with parental consent never received the first vaccine dosage, resulting in an overall uptake rate for consented children of about 99.3%. The completion rate of the two-dose regimen was significantly higher than the three-dose regimen (95.9% vs 87.8%; p<0.0001). A larger percentage of girls were sufficiently vaccinated in the second project where two doses were intended (95.9% vs 91.6%; p<0.0001) (Table 1).

Health Education

The questionnaires demonstrated a lack of knowledge about cervical cancer symptoms and prevention among mothers that improved significantly after attending health education events about the disease (Table 2: Knowledge). Data about knowledge improvement after receiving written information was not available, but information were distributed to more households when provided in a printed format (100% vs 28.6%) (Table 2).

Table 2

Questionnaire results

The median age of mothers/female guardians of girls in grades 4 to 7 was 38 years and of participants that accessed screening was 38.7 (SD 7.7) years. Levels of education varied widely (primary school: 10%; tertiary education: 21%) as did employment data (salaried: 50%; self-employed: 6.8%). Parents with children attending Gauteng schools were significantly younger and better educated16 (data not shown).

Screening

Self-reported screening behavior scores were similar for the different sites and improved in the total study after the invitation to participate. These data, however, did not correlate well with confirmed participation in screening (Table 3).18 We could confirm the screening uptake and participation of those who accepted the invitation to self-sample and deliver the specimen at the school (Table 4).

Table 3

Self-reported screening before and after the intervention (VACCS1)

Table 4

Screening coverage

The best estimate of screening uptake when participants were simply reminded to use existing facilities was the self-reported improvement of 24.5% in the second questionnaire translating into 10.7% of unscreened women. Screening uptake reached 43.9% of the study participants (28.6% of the total unscreened target group) when self-screening was offered either at a health education event (64.5%) or was sent home (32.8%) (p<0.0001) (Table 4).

Women who received self-screening kits at a health education event were much more likely to use it than when it was sent home (31.8% vs 16.4%; p<0.0001). Self-sampling kits were equally unused in large numbers during both studies by women who elected to take it home (VACCS1) and by those who received it at home in an envelope (VACCS2). Both methods resulted in 14.8% of the total target group being screened, translating to about 29.0% of the unscreened women (Table 4).

Throughout the project, 19.1% of screening tests were positive for high-risk HPV (hrHPV) and 8.6% were positive for HPV 16 and/or 18. As expected, tampon-collected samples tested with Roche Linear Array were slightly more sensitive than brush-collected samples tested with Roche Cobas. Although the numbers were small, Western Cape samples appeared to have a lower prevalence of abnormalities compared with Gauteng samples (Table 5).

Table 5

Screening results

Discussion

Summary of Main Results

During this HPV vaccine implementation study in primary schools, the overall vaccine uptake was 59.7%, and the need for parental informed consent (the opt-in model) was a significant barrier to vaccination. The consented uptake rate was close to 100%; vaccine completion rates and the rate of sufficiently vaccinated participants were best with the two-dose regimen.

Vaccination was successfully linked with knowledge transfer and screening of mothers using self-sampling and molecular tests, which were abnormal in 27.7% of women. Self-screening was superior to using the existing health facilities, which may still have been over-reporting as not all tests could be confirmed via electronic access to the national screening database.19 Women may not recall the time since their last screening test accurately and the results of these questions may also be influenced by social desirability bias. The age distribution of screened women mirrored the ideal screening target group, with most of the women being between 30 and 49 years of age.

Results in the Context of Published Literature

Reported vaccine acceptance for the target group varies from 10% to >90%.20 In a review of low- and middle-income countries, half of all opt-in studies reported uptakes above 90%; 33% reported uptakes of 70%–90%, while opt-out or implied consent was more successful.21 In the current study, using an opt-in consent approach, requiring both written informed parental consent and child assent, vaccine uptake was lower than most other reports, but probably is realistic and reflects a true-life situation without campaigns to motivate. While multiple factors are reported to influence uptake (type of vaccination program, coercion, time period of the study, income level of the participants, social media campaigns, or method to obtain consent), the true reasons for poor uptake are largely speculative.22

When vaccination rates are calculated per consented cohort, the vaccination rates of more than 99% are comparable to that reported in another early South African implementation study.23 Heterogeneity regarding reported completion rates, or “follow-through rates”, challenge comparison with the completion and sufficiently vaccinated rates calculated in the current study, which report on both two-dose and three-dose implementation.22 The rates of sufficiently or completely vaccinated girls in the two-dose leg of the study compares favorably with published data.24

Our demographic data confirm that mothers of vaccine recipients are an ideal target group for cervical cancer education and screening. Poor knowledge of disease detection and prevention has often been linked to high prevalence and late diagnosis of cervical cancer, but evidence about interventions that effectively addresses this problem is limited.25 Consistent with previous reports, the present study confirmed that South African women lack this basic knowledge.26 27 Importantly, in this report simple health education during a vaccine implementation project had a measurable and significant positive effect on the knowledge of mothers of primary school children. Furthermore, it was demonstrated that increased knowledge scores can be linked to improved screening behavior when screening was easy to access.16

Many methods have been tested to reach the unscreened population via self-sampling. In a meta-analysis which was performed according to the type of invitation used, participation rates varied widely. Door-to-door invitations in developing settings reached most women (92.4%), mailed self-sampling kits reached 20.7%, and mailed opt-in invitations had participation rates of only 9.7%.28 The overall screening participation rate among unscreened women in this study (29.5%) was similar for both methods of delivering sampling kits, and compares favorably to previously reported rates using mailed kits. Poor attendance was obtained using reminder invitation to existing screening facilities; this finding is in accordance with other reports.29

Strengths and Weaknesses

This school vaccine implementation project was performed in a real-life setting and linked to maternal education and screening. The study was performed in two provinces with very different demographics and in 29 schools to allow for the heterogeneity of the South African population. Other strengths were that different methods of inviting participation and different dosing regimens were used and compared.

Limitations include the shortcomings of administered questionnaires, difficulties in accurately assessing knowledge and attitudes, and the potential inaccuracy of self-reported data. Determinants of parental consent could not be studied because questionnaire results were unavailable for non-consenting parents. The self-reported response of participants invited to screen at existing clinics was probably an overestimate and was not supported by other data sources.

Implications for Practice and Further Research

HPV vaccination campaigns can be used to offer health education and screening. Written and audiovisual material can effectively address the education gap; self-sampling kits can reach unscreened mothers via this platform. The positive attitude among parents toward vaccination, and health-seeking-behavior for their children will hopefully contribute to widespread acceptance of HPV vaccine programs in South Africa and similar developing countries. Further research should explore the reasons for the relatively poor vaccine uptake in opt-in programs and methods to improve this uptake.

Conclusions

HPV vaccine programs can enable linked primary and secondary prevention of cervical cancer, targeting schoolgirls and mothers. Education, vaccination, and screening for cervical cancer control were all successfully combined in a single program. Mothers of primary school children are socially and economically critically important and are at the ideal age for cervical screening. HPV vaccine programs can reach unscreened mothers via self-collected molecular tests and school-based logistics.

In this study, parental informed consent was the major determinant of vaccine uptake, while the number of required doses was the major determinant of vaccine completion. The distribution of information was most successful when sent home in a written format, but there was a poor response to the request for remote consent. During educational events we obtained excellent parental consent rates and demonstrated an improvement in knowledge, but attendance was relatively poor. The final consent rate was therefore similar for the two approaches. The two-dose regimen achieved the best vaccine completion and sufficiently vaccinated rates.

Data availability statement

Data are available upon reasonable request.

Ethics statements

Patient consent for publication

Ethics approval

This study involves human participants and was approved by the Faculty of Health Sciences Research Ethics Committee, University of Pretoria (219/2009; 90/2013) and the Faculty of Health Sciences Research Ethics Committee, University of Stellenbosch (N11/01/008). Participants gave informed consent to participate in the study before taking part.

Acknowledgments

The authors gratefully acknowledge the contribution of the following groups and persons: the Cancer Research Initiative of South Africa (CARISA), the South African Medical Research Council (MRC), and Cancer Association of South Africa (CANSA): financial support; vaccine manufacturing companies GlaxoSmithKline/Aspen SA and MSD: vaccine donations; the First for Women Foundation: funds for screening; nurse research assistants and medical students: questionnaires and vaccination; all participating schools, management teams, girls, parents, and guardians.

References

Footnotes

  • Contributors GD, MHB, BG, and FHvdM designed the studies. LCS and FHvdM coordinated sites. CV coordinated the study and collated data. RB collected data. NL coordinated vaccination. BG coordinated vaccine donations. KR coordinated screening. PJB and JH performed statistical analysis. GD drafted the paper and acts as guarantor. MHB, LCS, CV, BG, and FHvdM reviewed the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.